Objective To evaluate the effect of combination of mesalazine and bifico on serum TNF-α,IL-10 levels in patients with ulcerative colitis( UC ). Methods Thirty-eight patients with UC were randomly divided into two groups:control group( n = 19 ) and treatment group( n = 19 ). Patients in control group were given mesalazine therapy, while patients in treatment group were additionally given bifico with 2 months as a course. Serum TNF-α, IL-10 levels were tested by double antibody- sandwich enzyme-linked immunosorbent assay- before and after treatment. Results After treatment,TNF-α levels in 2 groups decreased( P ＜0.05 ),while IL-10 level increased( P ＜ 0.05 ). The difference before and after treatment was statistically different between 2 groups( P ＜ 0.05 ). In treatment group, the decreased degree of clinical symptom score was obviously higher than in control group( P ＜ 0.05 ). Conclusion Compared with single use of mesalazine, combination of mesalazine and bifico can more effectively reduce serum level of TNF-α, and increase serum IL-10 level in patients with ulcerative colitis.%目的 探讨美沙拉嗪与培菲康联合治疗对溃疡性结肠炎(UC)患者血清TNF-α、IL-10的影响.方法 38例UC患者,随机分为两组:对照组和治疗组,各19例.对照组给予美沙拉嗪治疗,治疗组在此基础上加用培菲康,疗程均为2个月.治疗前后采用双抗体夹心酶联免疫吸附法测定血清TNF-α、IL-10的水平,并观察两组患者临床症状改善情况.结果 治疗组和对照组治疗后TNF-α的水平较治疗前均明显降低(P<0.05),IL-10较治疗前均明显升高(P<0.05);两组治疗前后差值比较,差异也有统计学意义(P<0.05).治疗组患者临床症状评分下降程度明显大于对照组(P<0.05),差异有统计学意义.结论 艾迪莎联合培菲康较单独使用艾迪莎治疗能够降低患者血清TNF-α、提高IL-10的水平.
展开▼
